Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Overexpression of RUNX1 short isoform has an important role in the development of myelodysplastic/myeloproliferative neoplasms.

Literature DB >> 29296779

Overexpression of RUNX1 short isoform has an important role in the development of myelodysplastic/myeloproliferative neoplasms.

Hiroko Sakurai¹, Yuka Harada^1,2, Yosuke Ogata², Yuki Kagiyama³, Naoki Shingai¹, Noriko Doki⁴, Kazuteru Ohashi⁴, Toshio Kitamura⁵, Norio Komatsu¹, Hironori Harada^1,3.

Abstract

RUNX1a, but not RUNX1b, is overexpressed in CD34+ cells from patients with myelodysplastic/myeloproliferative neoplasms.SRSF2P95H mutation induces RUNX1a overexpression and a monocytic phenotype in TF-1 cells.

Entities: Disease Gene Species

Year: 2017 PMID： 29296779 PMCID： PMC5727847 DOI： 10.1182/bloodadvances.2016002725

Source DB: PubMed Journal: Blood Adv ISSN： 2473-9529

19 in total

1. RUNX1a enhances hematopoietic lineage commitment from human embryonic stem cells and inducible pluripotent stem cells.

Authors: Dan Ran; Wei-Jong Shia; Miao-Chia Lo; Jun-Bao Fan; David A Knorr; Patrick I Ferrell; Zhaohui Ye; Ming Yan; Linzhao Cheng; Dan S Kaufman; Dong-Er Zhang
Journal: Blood Date: 2013-01-31 Impact factor: 22.113

2. Runx1 isoforms show differential expression patterns during hematopoietic development but have similar functional effects in adult hematopoietic stem cells.

Authors: Grant A Challen; Margaret A Goodell
Journal: Exp Hematol Date: 2010-03-03 Impact factor: 3.084

3. Frequent pathway mutations of splicing machinery in myelodysplasia.

Authors: Kenichi Yoshida; Masashi Sanada; Yuichi Shiraishi; Daniel Nowak; Yasunobu Nagata; Ryo Yamamoto; Yusuke Sato; Aiko Sato-Otsubo; Ayana Kon; Masao Nagasaki; George Chalkidis; Yutaka Suzuki; Masashi Shiosaka; Ryoichiro Kawahata; Tomoyuki Yamaguchi; Makoto Otsu; Naoshi Obara; Mamiko Sakata-Yanagimoto; Ken Ishiyama; Hiraku Mori; Florian Nolte; Wolf-Karsten Hofmann; Shuichi Miyawaki; Sumio Sugano; Claudia Haferlach; H Phillip Koeffler; Lee-Yung Shih; Torsten Haferlach; Shigeru Chiba; Hiromitsu Nakauchi; Satoru Miyano; Seishi Ogawa
Journal: Nature Date: 2011-09-11 Impact factor: 49.962

4. Architecture and anatomy of the genomic locus encoding the human leukemia-associated transcription factor RUNX1/AML1.

Authors: D Levanon; G Glusman; T Bangsow; E Ben-Asher; D A Male; N Avidan; C Bangsow; M Hattori; T D Taylor; S Taudien; K Blechschmidt; N Shimizu; A Rosenthal; Y Sakaki; D Lancet; Y Groner
Journal: Gene Date: 2001-01-10 Impact factor: 3.688

5. Runx1 exon 6-related alternative splicing isoforms differentially regulate hematopoiesis in mice.

Authors: Yukiko Komeno; Ming Yan; Shinobu Matsuura; Kentson Lam; Miao-Chia Lo; Yi-Jou Huang; Daniel G Tenen; James R Downing; Dong-Er Zhang
Journal: Blood Date: 2014-04-25 Impact factor: 22.113

6. LincRNA-uc002yug.2 involves in alternative splicing of RUNX1 and serves as a predictor for esophageal cancer and prognosis.

Authors: H Wu; J Zheng; J Deng; L Zhang; N Li; W Li; F Li; J Lu; Y Zhou
Journal: Oncogene Date: 2014-12-08 Impact factor: 9.867

Review 7. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors: Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal: Blood Date: 2016-04-11 Impact factor: 22.113

8. AML1 mutations induced MDS and MDS/AML in a mouse BMT model.

Authors: Naoko Watanabe-Okochi; Jiro Kitaura; Ryoichi Ono; Hironori Harada; Yuka Harada; Yukiko Komeno; Hideaki Nakajima; Tetsuya Nosaka; Toshiya Inaba; Toshio Kitamura
Journal: Blood Date: 2008-01-11 Impact factor: 22.113

9. Isoform-specific potentiation of stem and progenitor cell engraftment by AML1/RUNX1.

Authors: Shinobu Tsuzuki; Dengli Hong; Rajeev Gupta; Keitaro Matsuo; Masao Seto; Tariq Enver
Journal: PLoS Med Date: 2007-05 Impact factor: 11.069

10. The new provisional WHO entity 'RUNX1 mutated AML' shows specific genetics but no prognostic influence of dysplasia.

Authors: T Haferlach; A Stengel; S Eckstein; K Perglerová; T Alpermann; W Kern; C Haferlach; M Meggendorfer
Journal: Leukemia Date: 2016-05-23 Impact factor: 11.528

8 in total

1. A CRISPR RNA-binding protein screen reveals regulators of RUNX1 isoform generation.

Authors: Amanda G Davis; Jaclyn M Einstein; Dinghai Zheng; Nathan D Jayne; Xiang-Dong Fu; Bin Tian; Gene W Yeo; Dong-Er Zhang
Journal: Blood Adv Date: 2021-03-09

Review 2. Myeloid neoplasms and clonal hematopoiesis from the RUNX1 perspective.

Authors: Yoshihiro Hayashi; Yuka Harada; Hironori Harada
Journal: Leukemia Date: 2022-03-30 Impact factor: 11.528

Review 3. Molecular Pathogenesis of Myeloproliferative Neoplasms: From Molecular Landscape to Therapeutic Implications.

Authors: Erika Morsia; Elena Torre; Antonella Poloni; Attilio Olivieri; Serena Rupoli
Journal: Int J Mol Sci Date: 2022-04-20 Impact factor: 6.208

4. RUNX1 upregulation via disruption of long-range transcriptional control by a novel t(5;21)(q13;q22) translocation in acute myeloid leukemia.

Authors: Chi-Keung Cheng; Terry H Y Wong; Thomas S K Wan; Angela Z Wang; Natalie P H Chan; Nelson C N Chan; Chi-Kong Li; Margaret H L Ng
Journal: Mol Cancer Date: 2018-08-29 Impact factor: 27.401